Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience

BACKGROUND: The global lapatinib expanded access programme provided access to lapatinib combined with capecitabine for women with HER2-positive metastatic breast cancer (MBC) who previously received anthracycline, taxane and trastuzumab. METHODS: Progression-free survival (PFS) and safety data for 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutherland, S, Ashley, S, Miles, D, Chan, S, Wardley, A, Davidson, N, Bhatti, R, Shehata, M, Nouras, H, Camburn, T, Johnston, S R D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844035/
https://www.ncbi.nlm.nih.gov/pubmed/20179708
http://dx.doi.org/10.1038/sj.bjc.6605586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844035/
https://www.ncbi.nlm.nih.gov/pubmed/20179708
http://dx.doi.org/10.1038/sj.bjc.6605586

Ejemplares similares